WGS stock forecast, quote, news & analysis
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders... Show more
Why Is GeneDx Holdings (WGS) Stock Down -48.54% Today?
Key Takeaways
- GeneDx Holdings (WGS) shares plunged 48.54% to close at $34.95, following the previous close of $67.93.
- Primary catalyst: Q1 2026 earnings miss with EPS of -$0.28 versus expected -$0.06, and revenue of $102.3 million missing consensus of $112.5 million.
- Company slashed full-year 2026 revenue guidance to $475-$490 million from $540-$555 million, citing reimbursement pressures and non-core softness.
- Trading volume exploded to over 4.2 million shares, versus average of ~750,000, indicating heavy selling pressure.
- Move sharply diverged from flat healthcare sector peers like XLV ETF (-0.18% prior day).
- Traders watching Q2 guidance execution, reimbursement trends, and exome/genome volume growth of at least 30%.
Opening Summary
GeneDx Holdings Corp. (WGS), a genomics company specializing in pediatric and rare disease diagnostics through exome and genome sequencing, saw its stock plummet 48.54% in the most recent trading session. Shares closed at $34.95, down from the prior close of $67.93. The steep decline stemmed from disappointing Q1 results and a sharp cut to full-year guidance, triggering a swift market reaction.
Q1 Earnings Miss
GeneDx reported Q1 revenue of $102.3 million, up 17% year-over-year but short of the $112.5 million expected. Exome and genome revenue rose 27% to $90.6 million, with test volumes up 34% to 27,488. However, the adjusted EPS loss widened to -$0.28 from forecasts of -$0.06, driven by blended average reimbursement rates and weakness in non-core segments. The results highlighted ongoing pressures in reimbursement and market expansion, eroding investor confidence in near-term profitability.
Downward Revision to Full-Year Guidance
Management updated 2026 outlook, lowering revenue expectations to $475-$490 million—a 12% cut from prior $540-$555 million midpoint—due to $36 million in reimbursement impacts, softer expansion volumes, and non-core declines. Exome/genome growth was trimmed to at least 30% volumes (20% revenue), with adjusted gross margins steady at ~70%. Q2 revenue guided to $110-$112 million, well below consensus of $130 million. The guidance slash amplified the earnings disappointment, prompting the stock's plunge.
Market Context and Trading Activity
Volume surged to over 4.2 million shares, more than 5x the 750,000 average, reflecting intense selling post-earnings. The drop diverged from broader healthcare, where the XLV ETF edged down 0.18% and IBB biotech ETF gained modestly prior session. WGS breached key support near $65, its 50-day moving average, accelerating the decline amid high short interest (~15% of float). Broader indices were mixed, underscoring the company-specific catalyst.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform’s top-performing AI-driven trading bots amid current market dynamics. Tickeron deploys hundreds of specialized bots across thousands of tickers, employing diverse strategies like momentum, mean reversion, and pattern recognition over various timeframes. Only those demonstrating superior risk-adjusted returns, win rates, and adaptability to volatility earn a spot in this curated leaderboard. Metrics such as Sharpe ratio, maximum drawdown, and recent performance highlight standouts. Investors can explore, backtest, and deploy these bots to automate trading—explore the page to identify tools suited to your portfolio.
What Comes Next for WGS
GeneDx focuses on executing revised guidance, with Q2 revenue targeted at $110-$112 million and emphasis on 30%+ exome/genome volumes. Next earnings are slated for early August, covering Q2 results amid scrutiny on reimbursement recovery and core growth. Analyst expectations center on profitability inflection, with full-year adjusted net income positive. Sector risks include reimbursement policy shifts and competition in genomics. Uncertainties around payer negotiations and non-core stabilization loom, alongside opportunities in AI-enhanced diagnostics.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
Aroon Indicator for WGS shows an upward move is likely
WGS's Aroon Indicator triggered a bullish signal on June 25, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 171 similar instances where the Aroon Indicator showed a similar pattern. In of the 171 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on May 19, 2026. You may want to consider a long position or call options on WGS as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for WGS just turned positive on May 20, 2026. Looking at past instances where WGS's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .
WGS moved above its 50-day moving average on June 11, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for WGS crossed bullishly above the 50-day moving average on June 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 10 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where WGS advanced for three days, in of 270 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where WGS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
WGS broke above its upper Bollinger Band on June 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. WGS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.472) is normal, around the industry mean (12.429). WGS has a moderately high P/E Ratio (739.818) as compared to the industry average of (145.823). WGS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.482). WGS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.008). P/S Ratio (3.623) is also within normal values, averaging (7.248).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WGS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalSpecialties